title: Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study.
abstract: BACKGROUND
  Antiretroviral therapy (ART) affects cardiovascular disease (CVD) risk. In the general population, highly sensitive creactive protein (hsCRP) is an established predictor of future coronary events. Little is known about its utility in chronic inflammatory conditions such as HIV infection. We assessed relationships between hsCRP and metabolic parameters over time in HIV-infected patients on ART.
  
  
  METHODS
  Data are from a prospective cohort of HIV-infected adults enrolled June 2005 to July 2007. Participants were receiving ART, had HIV-1 RNA,10,000 copies per milliliter, and no diabetes or CVD. Nonlinear mixed-effect regression models assessed relationships between body mass index (BMI), lipids, and hsCRP over time adjusting for covariates.
  
  
  RESULTS
  Ninety-four individuals had data from $1 study visit. Median age was 44 years, 27% were female, 57% white, and 54% were on protease inhibitors. Median CD4+ T cells, HIV-1 RNA, and hsCRP were 502 cells per cubic millimeter, 50 copies per milliliter, and 2.94 mg/dL, respectively. Median Framingham score was 3. Multivariate analysis identified associations between increased hsCRP and greater BMI (P = 0.001), higher non-high-density lipoprotein cholesterol (P = 0.013) and triglycerides (P = 0.017), and lower high-density lipoprotein cholesterol (P = 0.015).
  
  
  CONCLUSIONS
  Among HIV-infected adults with low estimated CVD risk and virologic suppression on ART, hsCRP was elevated and independently associated with BMI and lipid changes. Future studies should assess associations between hsCRP and clinical outcomes.
authors.affiliation: Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine,Nashville, TN, USA. michael.boger@vanderbilt.edu
authors.forename: Michael S
authors.initials: MS
authors.lastname: Boger
authors.forename: Ayumi
authors.initials: A
authors.lastname: Shintani
authors.forename: Leigh Anne
authors.initials: LA
authors.lastname: Redhage
authors.forename: Valerie
authors.initials: V
authors.lastname: Mitchell
authors.forename: David W
authors.initials: DW
authors.lastname: Haas
authors.forename: Jason D
authors.initials: JD
authors.lastname: Morrow
authors.forename: Todd
authors.initials: T
authors.lastname: Hulgan
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008055:Lipids / Q000097:blood*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012307:Risk Factors
chemical_list: D019380:Anti-HIV Agents; D008055:Lipids; D002097:C-Reactive Protein